- Portage Biotech Inc PRTG has updated its clinical development programs and announced its development goals for 2022, and it continues to work toward multiple clinical readouts in 2022.
- In 2021, clinical trials for Portage's lead invariant natural killer T cell (iNKT) agonist programs, PORT-2 and PORT-3, were initiated.
- Preliminary Phase 1 data suggest PORT-2 was well tolerated when administered as a monotherapy, with no related adverse events.
- PORT-2, an iNKT agonist to treat melanoma and non-small cell lung cancer (NSCLC), is currently in Phase 1/2 trial.
- Initial efficacy data is anticipated by the end of 2022.
- The Company has accelerated the opening of the combination safety cohort with Merck & Co Inc's MRK Keytruda in parallel with the ongoing high-dose monotherapy cohort.
- Preliminary safety data for repeat dosing of PORT-3, a nanoparticle co-formulation of PORT-2 and NY-ESO-1 immunogenic peptides for NY-ESO-1 positive solid tumors, is also favorable.
- Phase 1/2 is ongoing with preliminary efficacy data in patients expected year-end, going into 2023.
- PORT-1 intratumoral amphiphilic formulation is being evaluated as a monotherapy combined with Merck's Keytruda and Bristol-Myers Squibb Co's BMY Yervoy to treat multiple solid tumors (Phase 2).
- Multiple readouts are expected in 2H 2022.
- Price Action: PRTG shares closed 0.58% lower at $6.83 on Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.